Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check8 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check29 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check58 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for those interested in joining the study, along with a reference to the Contacts and Locations section.SummaryDifference3%
Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.